- The U.S. authorities initiatives Leqembi, the newly accredited Alzheimer’s remedy from Biogen (NASDAQ:BIIB), will price $3.5B throughout all the Medicare program in 2025, far increased than its co-developer Eisai (OTCPK:ESAIY) (OTCPK:ESALF) estimates, Stat Information reported.
- A doc from a February name on the Facilities for Medicare & Medicaid Providers (CMS) indicated that the per member spending on the anti-amyloid remedy will attain $4.67 per thirty days in 2025, up from $1.67 in 2024.
- That suggests about $550M for conventional Medicare and $3.5B for all the Medicare program in 2025, Stat reported.
- In March, Eisai (OTCPK:ESAIY) set its 2026 gross sales forecast for the drug at $1.9B (¥290B). After profitable full FDA approval in July 2023, the Japanese drugmaker launched Leqembi with its U.S. accomplice Biogen (BIIB) at an annual listing value of $26.5K per affected person earlier than reductions or rebates.